Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for Recently Diagnosed COVID-19 ...Middle East

Indianapolis, IN…The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single int

Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for Recently Diagnosed COVID-19 )

Also on site :

• On the record: Hubbard
• ForexLive Asia-Pacific FX news wrap: Oil spike on talk of Israel preparing attack on Iran
• ‘My Life Is Complete’: 'Days of Our Lives' Star Shares Emotional First Look at Full Hernandez Family